stephen silberstein, md, director, jefferson university headache center. .
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv). .
"we are calling for the immediate implementation of a statutory duty of candour for the health trusts." .